KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study.

Jeffrey D Bradley, Shunichi Sugawara, Ki Hyeong Lee, Gyula Ostoros, Ahmet Demirkazik, Milada Zemanova, Virote Sriuranpong, Ana Caroline Zimmer Gelatti, Juliana Janoski de Menezes, Bogdan Zurawski, Michael Newton, Pratibha Chander, Nan Jia, Zofia F Bielecka, Mustafa Özgüroğlu, PACIFIC-2 Investigators

J Clin Oncol 43(33) 3610-3621

PMID41082707
PMCIDPMC12622289
DOI10.1200/JCO-25-00036
发表日期2025-10-13
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: Immunotherapy targeting PD-L1 improves outcomes in patients with unresectable stage III non-small cell lung cancer (NSCLC) and no progression after definitive, concurrent chemoradiotherapy (cCRT). Earlier administration of immunotherapy, simultaneously with cCRT, may improve outcomes further. METHODS: Eligible patients were randomly assigned (2:1) to receive either durvalumab or placebo administered from the start of cCRT. Patients without progression after completing cCRT received consolidation durvalumab or placebo (per initial random assignment) until progression. The primary end point was progression-free survival (PFS) by blinded independent central review. Key secondary end points included objective response rate (ORR), overall survival (OS), the proportion of patients alive at 24 months (OS24), and safety. RESULTS: In total, 328 patients were randomly assigned to receive durvalumab (n = 219) or placebo (n = 109). There was no statistically significant difference with durvalumab versus placebo in PFS (hazard ratio [HR], 0.85 [95% CI, 0.65 to 1.12]; P = .247) or OS (HR, 1.03 [95% CI, 0.78 to 1.39]; P = .823); OS24 was 58.4% versus 59.5%, respectively. Confirmed ORR was 60.7% with durvalumab versus 60.6% with placebo (difference, 0.2% [95% CI, -15.2 to 16.3%]; P = .976). With durvalumab versus placebo, respectively, maximum grade 3 or 4 adverse events (AEs) occurred in 53.4% versus 59.3% of patients, pneumonitis or radiation pneumonitis (group term) in 28.8% (grade ≥3: 4.6%) versus 28.7% (grade ≥3: 5.6%), AEs leading to discontinuation of durvalumab or placebo in 25.6% versus 12.0%, and fatal AEs in 13.7% versus 10.2%. CONCLUSION: Among patients with unresectable stage III NSCLC, durvalumab administered from the start of cCRT failed to demonstrate additional benefit compared with cCRT plus placebo. Consolidation durvalumab following definitive cCRT remains the standard of care in this setting.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

FIG 2.

FIG 2. Kaplan-Meier analysis of (A) PFS by BICR and (B) OS (ITT population). Tick marks on the curves indicate censored observations. PFS per RECIST v1.1. PFS and OS were analyzed using a stratified log-rank test adjusting for age and disease stage, with HRs and 95% CIs estimated using a Cox proportional hazards model. Kaplan-Meier methodology was used to calculate medians for time-to-event end points. Data cutoff date, September 7, 2023. a Based on the Lan and DeMets approach that approximates the O'Brien Fleming spending functions; the two-sided P value boundary for declaring statistical significance for PFS is .0416 for an overall 5% alpha. b The two-sided P value boundary for declaring statistical significance for OS is .045 or .05 depending on the previous levels of the multiple testing procedure. BICR, blinded independent central review; CRT, chemoradiotherapy; HR, hazard ratio; ITT, intention-to-treat; OS, overall survival; PFS, progression-free survival.

A

PFS

FIG 2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:flat topline artifact曲线 2:short span
查看结果
B

OS

FIG 2. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. Patient disposition. a The safety analysis set includes all patients who underwent random assignment and received at least one dose of trial treatment or placebo; one patient assigned to the placebo group erroneously received a single cycle of durvalumab and was included in the durvalumab group for the safety analysis set. CRT, chemoradiotherapy; ITT, intention-to-treat.
非 KM Figure
FIG 3.FIG 3. Forest plots of (A) PFS by BICR and (B) OS in prespecified patient subgroups (ITT population). PFS per RECIST v1.1. An HR of < 1 favors durvalumab and is associated with a longer PFS/OS than placebo. The size of circle is proportional to the number of events. The gray band represents the 95% CI for the main PFS/OS HR. For all patients, the analysis is based on the main stratified analysis, whereas for the subgroups, the HR and CI were calculated using an unstratified Cox proportional hazards model, with treatment as the only covariate and ties handled by Efron approach. Data cutoff date, September 7, 2023. a HRs and 95% CIs were not calculated if a subgroup had fewer than five events in either treatment arm. b At screening. c According to version 8 of the IASLC Staging Manual in Thoracic Oncology. d Per IVRS. BICR, blinded independent central review; EGFR, epidermal growth factor receptor; HR, hazard ratio; IASLC, International Association for the Study of Lung Cancer; ITT, intention-to-treat; IVRS, interactive voice response system; NC, not calculable; OS, overall survival; PFS, progression-free survival.
非 KM Figure